Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
EXCH
Pangen Biotech
★

Pangen Biotech Selected as Negotiation Partner for KNIH's SFTS Therapeutic Antibody R&D Project – KRW 2.75 Billion Government Contract

  05/27/2026, 02:17 PM
PERI
Pangen Biotech
★

PanGen Q1 2026: Revenue 3.73B KRW, Operating Profit Down but Net Profit Up, Debt Ratio 9%

  05/14/2026, 10:55 AM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.